CLINICAL USE

Thrombolytic:Acute myocardial infarction

DOSE IN NORMAL RENAL FUNCTION

30–50 mg depending on patient weight (500–600 micrograms/kg)

PHARMACOKINETICS

  • Molecular weight                           :70 000
  • %Protein binding                           :No data
  • %Excreted unchanged in urine     : Minimal
  • Volume of distribution (L/kg)       :6.1–9.1 litres1 (weight and dose related)
  • half-life – normal/ESRD (hrs)      :90–130 minutes/Unchanged

    DOSE IN RENAL IMPAIRMENT

    GFR (mL/MIN)

  • 20 to 50     : Dose as in normal renal function
  • 10 to 20     : Dose as in normal renal function
  • <10           : Dose as in normal renal function

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

  • CAPD                :Unlikely to be dialysed. Dose as in normal renal function
  • HD                     :Unlikely to be dialysed. Dose as in normal renal function
  • HDF/high flux   :Unknown dialysability. Dose as in normal renal function
  • CAV/VVHD      :Unknown dialysability. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS

    Potentially hazardous interactions with other drugsDrugs that affect coagulation or platelet function: increased risk of bleeding

    ADMINISTRATION

    Reconstition

    Water for injection

    Route

    IV

    Rate of Administration

    Over 10 seconds

    Comments

    Incompatible with dextrose

    OTHER INFORMATION

    It has an initial half-life of 20–24 minutes Cleared mainly by hepatic metabolism Re-administration is not recommended due to lack of experience

    • Tags:

    Related News

    ffddfd

    Hyperlipidemia